ABT ABT アボットラボラトリ―ズ



symbol ABT
会社名 Abbott Laboratories (ABT アボットラボラトリ―ズ)
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 アボットラボラトリーズ(Abbott Laboratories)はヘルスケア製品の発見、開発、製造及び販売に従事する企業である。同社は上場医薬品、診断薬、栄養剤、血管製品の4つの事業区分により構成される。上場医薬品は世界各地で製造され、各種ブランドのジェネリック医薬品を含む。診断製品には、診断システムとテストが含まれる。栄養製品には、小児用および成人用の栄養製品が含まれる。同社の血管製品には、血管疾患の治療のための冠状動脈、血管内血管、血管閉鎖および構造的心臓装置が含まれる。同社はSt. Jude Medical Incを通じてリズム管理製品、電気生理学製品、心不全関連製品、血管製品、構造用心臓製品、神経調節製品などの製品を提供する。  アボット・ラボラトリ―ズは米国の大手医薬品メ―カ―。リウマチ性関節炎用「ヒュミラ」、脂質異常症治療薬「トライコア」、HIV感染症治療薬「カレテラ」、前立腺がん治療薬「リュ―プロン」などを製造。ジェネリックも展開し、試薬、遺伝子検査キット、栄養補助食品「エンシュア」、血糖値自己測定器「フリ―スタイル」などを扱う。本社はイリノイ州。  Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
本社所在地 224 667-6100
代表者氏名 Miles D White
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 224-667-6100
設立年月日 61
市場名 NYSE(ニューヨーク証券取引所)
従業員数 103000人
url www.abbott.com
EBITDA EBITDA(百万ドル) 7008.00000
時価総額 時価総額(百万ドル) 140412.20000
売上高 売上高(百万ドル) 30578.00000
企業価値(EV) 企業価値(EV)(百万ドル) 155892.20000
当期純利益 当期純利益(百万ドル) 2464.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Abbott Laboratories revenues increased 12% to $30.58B. Net income before extraordinary items increased 36% to $2.46B. Revenues reflect Diagnostics Products segment increase of 33% to $7.5B Vascular Products segment increase of 6% to $9.44B Other segment increase of 21% to $2B All other Countries segment increase of 95% to $11.22B United States segment increase of 12% to $10.84B.



   Abbott Analyst: Expert View On Rapid Coronavirus Antigen Test 'Clearly Bullish'  2020/08/31 15:21:33 Benzinga
Abbott Laboratories (NYSE: ABT ) shares rallied Thursday after the company's rapid COVID-19 test received emergency use authorization from the FDA . The Abbott Analyst: Bob Hopkins reiterated a Buy rating on Abbott Laboratories and increased the price target from $110 to $122. The Abbott Thesis: BofA Securities held a call with a virology and microbiology expert regarding Abbott's test, Hopkins said in a Monday note. (See his track record here .) The expert's view on Abbott's COVID-19 test was "clearly bullish," the analyst said; BofA did not name the expert in the note. Until real world data becomes available likely later this year, questions regarding accuracy in asymptomatic patients will remain unanswered, Hopkins said. Even if the sensitivity … Full story available on Benzinga.com
   Insights on the Continuous Glucose Monitoring Device Global Market to 2026 - Featuring Abbott Laboratories, Medtronic & Novo Nordisk Among Others - ResearchAndMarkets.com  2020/08/31 10:02:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Continuous Glucose Monitoring Device Market By Component, By End User, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Continuous Glucose Monitoring Device Market size is expected to reach $8.5 billion by 2026, rising at a market growth of 12.4% CAGR during the forecast period. Continuous Glucose Monitoring (CGM) is one of the newest advances in diabetes management technology. CGM
   Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories? | The Motley Fool  2020/08/30 13:06:00 The Motley Fool
One stock appears to be the clear winner in a matchup between these big coronavirus-focused healthcare companies.
   Abbott Expanding Its Covid-19 Test To Asymptomatic People- Report  2020/08/30 07:24:53 Smarter Analyst
Abbott Laboratories (ABT) is now holding trials to try and expand its rapid Covid-19 test to people who show no symptoms of the virus, … The post Abbott Expanding Its Covid-19 Test To Asymptomatic People- Report appeared first on Smarter Analyst .
   Abbott is testing its rapid coronavirus test on asymptomatic people in hopes of expanding FDA authorization  2020/08/28 21:22:01 CNBC
"We are running our clinical trial and we'll eventually have data to be able to support that," Abbott Laboratories CEO Robert Ford told CNBC.
   Abbott is testing its rapid coronavirus test on asymptomatic people in hopes of expanding FDA authorization  2020/08/28 21:22:01 CNBC
"We are running our clinical trial and we'll eventually have data to be able to support that," Abbott Laboratories CEO Robert Ford told CNBC.
   Jim Cramer: Abbott Labs and the Rally in Travel  2020/08/28 17:51:54 The Street RealMoney
ABT will end the issues of flying and cruising. Of course it's another story when you get there. But boarding will be solved….ABT
   Thinking about trading options or stock in Advanced Micro Devices, Inc., Abbott Laboratories, BMC Stock Holdings Inc, Nutanix Inc, or Royal Caribbean Cruises Ltd?  2020/08/28 13:31:00 PR Newswire
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, ABT, BMCH, NTNX, and RCL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
   Trump to announce a $750m deal to buy 150m rapid Covid-19 tests from Abbott Labs  2020/08/27 20:14:07 Forexlive
Thursday in Asia time brought news of the rapid test receiving approval: White House senior adviser Alyssa Farah: No schedule has been set for Trump's announcement. By Eamonn Sheridan
   Trump to Announce Deal With Abbott Laboratories for 150 Million Rapid Covid-19 Tests  2020/08/27 19:15:00 The Wall Street Journal
President Trump is expected to announce a $750 million deal to buy 150 million rapid Covid-19 tests from Abbott Laboratories, a move that would substantially expand the nation’s capacity for rapid testing.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ABT アボットラボラトリ―ズ ABT )


 twitter  (公式ツイッターやCEOツイッターなど)